- Boehringer Ingelheim Ltd (BIL) is seeking to appeal a decision regarding whether payments made to the Department of Health and Social Care (DHSC) under voluntary price control schemes should reduce the taxable amount of their pharmaceutical supplies.
- The initial FTT ruled that these payments did reduce the value of BIL’s supplies, considering the DHSC as the economic final consumer. However, the Upper Tribunal (UT) largely overturned this, stating that only payments related to excess sales growth for vaccines and medicines supplied directly to the DHSC could adjust VAT.
- The UT’s decision means that BIL cannot adjust the taxable amount for supplies made to wholesalers and pharmacies, limiting the scope for VAT reduction based on these payments.
Source KPMG
Latest Posts in "United Kingdom"
- UK–GCC Free Trade Agreement: A Landmark Deal Opening New Trade and Customs Opportunities
- HMRC Guidance: Business entertainment (VAT Notice 700/65)
- HMRC Guidance: Admission charges to cultural events (VAT Notice 701/47)
- HMRC Guidance: VAT rates on different goods and services
- Chefs Urge VAT Cut to Ease Restaurant Cost Pressures













